Global Lung Cancer Liquid Biopsy Market
Market Size in USD Billion
CAGR :
% 
USD
0.30 Billion
USD
1.38 Billion
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 0.30 Billion |
 Market Size (Forecast Year) |
USD 1.38 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Lung Cancer Liquid Biopsy Market, By Biomarker Type (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), Application (Small Cell Lung Cancer and Non-Small Cell Lung Cancer), End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers and Others) – Industry Trends and Forecast to 2030.
Lung Cancer Liquid Biopsy Market Analysis and Size
According to the National Cancer Institute, lung cancer is the leading cause of death in the United States. Lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer deaths worldwide, with an estimated 1.8 million new cases in 2012. Currently, the 5-year overall survival rate for lung cancer is 17%-22%, though survival varies depending on the stage of diagnosis. Liquid biopsy has enormous potential in lung cancer diagnosis.
Data Bridge Market Research analyses that the lung cancer liquid biopsy market which was USD 0.30 billion in 2022, is expected to reach USD 1.38 billion by 2030, at a CAGR of 21% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lung Cancer Liquid Biopsy Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Biomarker Type (CTC (Circulating Tumor Cells), ctDNA (Circulating tumor DNA), Exosomes and RNA), Application (Small Cell Lung Cancer and Non-Small Cell Lung Cancer), End-User (Diagnostic and Imaging Centres, Hospitals, Academic and Research Centers and Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Eurofins Scientific (Luxembourg), MDxHealth (Belgium), CareDx (U.S.), Immucor (U.S.), Thermo Fisher Scientific Inc. (U.S.), Menarini Silicon Biosystems (U.S.), QIAGEN (Germany), Guardant Health (U.S.), Exact Sciences Corporation (U.S.), Myriad Genetics, Inc. (U.S.), LungLife AI, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies Inc. (U.S.), Natera, Inc. (U.S.), CARDIFF ONCOLOGY, INC. (U.S.), Exosome Diagnostics Inc. (U.S.), Illumina, Inc. (U.S.), Genomic Health Inc. (U.S.) and F. Hoffmann-La Roche Ltd (Switzerland) |
|
Market Opportunities |
|
Market Definition
Liquid biopsy is a non-invasive alternative to surgical biopsies that aids in detecting molecular biomarkers. Liquid biopsy eliminates the need for costly invasive procedures by allowing doctors to detect diseases and make decisions using a blood sample from the patient. Liquid biopsy is a non-invasive alternative to surgical biopsies for detecting molecular biomarkers. Liquid biopsy is an essential component of precision medicine, with enormous diagnostic and treatment implications for oncology that can result in radical changes in clinical practice. It allows doctors to detect the onset of a disease or tumour by analyzing a simple blood sample. The presence of cancer cells or traces of RNA or DNA from cancer cells in the blood helps to determine the best course of treatment for a patient.
Global Lung Cancer Liquid Biopsy Market Dynamics
Drivers
- Rising incidence of lung cancer
The rising incidence of lung cancer is one of the primary drivers of the lung cancer liquid biopsy market. Lung cancer is the leading cause of cancer death worldwide. The main causes of the rising prevalence of lung cancer are smoking, passive smoking, air pollution, and genetic abnormalities. These are the certain reasons which boost the growth of the market.
- Rising use of personalized medicine
The liquid biopsy results can help physicians determine the treatment pattern for patients. These benefits are supplementing vendors' focus on providing a personalized treatment plan to lung cancer patients. Personalized medicine ensures that medications are targeted and effective. One of the key factors expected to positively impact the lung cancer liquid biopsy market during the forecast period.
Opportunities
- Growing awareness of patient and health-care professional
Growing patient and health-care professional awareness have increased the number of diagnosed lung cancer cases in Asia, particularly in China and India. The factors such as an increase in the number of reported lung cancer cases and significant investments in R&D of effective treatment alternatives in the region, North America is expected to dominate the global lung cancer liquid biopsy market in the near future.
Restraints/Challenges
- Lung cancer misdiagnosis
Lung cancer misdiagnosis, inadequate tumour sampling, and delayed diagnoses are also common due to limitations of the tissue biopsy will obstruct the market's growth rate.
This lung cancer liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Lung Cancer Liquid Biopsy Market
COVID-19 has infected approximately 532 million people worldwide. According to the most recent World meters’ statistics, the global death toll has reached 6,311,594. (as of May 31, 2022). The number is still growing, and the duration of the pandemic remains unknown. The impact of the COVID-19 pandemic on societies and economies around the world cannot be overstated. During the forecast period, the COVID-19 global pandemic has slowed the growth rate of the lung cancer liquid biopsy market.
Global Lung Cancer Liquid Biopsy Market Scope
The lung cancer liquid biopsy market is segmented on the basis of biomarker type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Biomarker Type
- CTC (Circulating Tumor Cells)
- ctDNA (Circulating tumor DNA)
- Exosomes and RNA
Application
- Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
End-User
- Diagnostic and Imaging Centres
- Hospitals
- Academic and Research Centers
- Others
Lung Cancer Liquid Biopsy Market Regional Analysis/Insights
The lung cancer liquid biopsy market is analyzed and market size insights and trends are provided by country, biomarker type, application and end-user as referenced above.
The countries covered in the lung cancer liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the lung cancer liquid biopsy market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the high CAGR in the forecast period and due to large patient pool in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The lung cancer liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer liquid biopsy market. The data is available for historic period 2011-2021.
Competitive Landscape and Lung Cancer Liquid Biopsy Market Share Analysis
The lung cancer liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer liquid biopsy market.
Some of the major players operating in the lung cancer liquid biopsy market are:
- Eurofins Scientific (Luxembourg)
- MDxHealth (Belgium)
- CareDx (U.S.)
- Immucor (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Menarini Silicon Biosystems (U.S.)
- QIAGEN (Germany)
- Guardant Health (U.S.)
- Exact Sciences Corporation (U.S.)
- Myriad Genetics, Inc. (U.S.)
- LungLife AI, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Agilent Technologies Inc. (U.S.)
- Natera, Inc. (U.S.)
- CARDIFF ONCOLOGY, INC. (U.S.)
- Exosome Diagnostics Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Genomic Health Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
Research Methodology: Global Lung Cancer Liquid Biopsy Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LUNG CANCER LIQUID BIOPSY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL LUNG CANCER LIQUID BIOPSY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEOMOLOGY MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 PATENT ANALYSIS
5.4 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 INCIDENCE AND PREVALENCE OF LUNG CANCER
6.1.1 REGIONAL
6.1.2 COUNTRY
6.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 DIAGNOSIS RATE BY MATURED MARKETS
7.5 INTERVIEWS WITH MANUFACTURING COMPANIES
7.6 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY PRODUCT
9.1 OVERVIEW
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB SEGMENTS)
9.2 INSTRUMENTS
9.2.1 BY TYPE
9.2.1.1. CONVENTIONAL PCR
9.2.1.2. REAL-TIME RT-PCR
9.2.1.3. DIGITAL PCR
9.2.1.4. MICROCSOPE
9.2.1.5. ULTRACENTRIFUGATION MACHINE
9.2.1.6. MICROPLATE READER
9.2.1.7. OTHERS
9.2.2 BY MODALITY
9.2.2.1. FIXED
9.2.2.2. MOBILE
9.2.3 BY USAGE
9.2.3.1. MANUAL
9.2.3.2. AUTOMATIC
9.2.3.3. SEMI-AUTOMATIC
9.3 KITS AND CONSUMBALES
9.3.1 KITS
9.3.1.1. BLOOD DNA EXTRACTION KIT
9.3.1.2. CELL-FREE TOTAL NUCLEIC ACID ISOLATION KIT
9.3.1.3. CELL-FREE DNA ISOLATION KIT
9.3.1.4. TISSUE DNA EXTRACTION KIT
9.3.1.5. ANTIBODY KIT
9.3.1.6. METHYLATED GENES KIT
9.3.2 CALL FREE DNA COLLECTION TUBE
9.3.3 RNA COLLECTION TUBE
9.3.4 SAMPLE PREPARATION CONSUMABLES
9.3.5 DNA FRAGMENTATION & AMPLIFICATION
9.3.6 LIBRARY PREPARATION & TARGET ENRICHMENT
9.3.7 QUALITY CONTROL
9.3.8 OTHER CONSUMABLES
9.4 SERVICES
10 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY BIOMARKER
10.1 OVERVIEW
10.2 CIRCULATING TUMOR CELL
10.2.1 IMMUNE ENRICHMENT METHOD
10.2.1.1. IMMUNOMAGNETIC BEAD METHOD
10.2.1.1.1. POSITIVE-ENRICHMENT METHOD
10.2.1.1.2. NEGATIVE-ENRICHMENT METHOD
10.2.1.2. IMMUNOADSORPTION METHOD
10.2.2 PHYSICAL ENRICHMENT METHOD
10.3 CIRCULATING TUMOR DNA
10.3.1 NEXT GENERATION SEQUENCING
10.3.2 REAL TIME PCR
10.3.3 DIGITAL DROPLET PCR
10.3.4 SCORPION AMPLIFICATION REFRACTORY MUTATION SYSTEMS
10.3.5 PEPTIDE NUCLEIC ACID‐LOCKED NUCLEIC ACID PCR
10.4 MICRO RNA
10.4.1 RNA SEQUENCENCING
10.4.2 MICROARRAYS
10.4.3 REAL TIME PCR
10.5 TUMOR-EDUCATED PLATELETS
10.5.1 ULTRA-DEEP
10.5.2 MASSIVE PARALLEL
10.5.3 LONG-READ SEQUENCING
10.6 TUMOUR DERIVED EXOSOMES
10.6.1 EV ARRAY
10.6.2 IMMUNOAFFINITY‐BASED TECHNIQUESULTRACENTRIFUGATION
10.6.2.1. ELISA
10.6.2.2. WESTERN BLOT
10.6.3 DENSITY GRADIENT
10.6.4 MICROFLUIDICS‐BASED
10.6.5 NANOTECHNOLOGY
10.6.6 OTHERS
11 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY SAMPLE
11.1 OVERVIEW
11.2 BLOOD
11.3 URINE
11.4 SALIVA
11.5 PLEURAL FLUID
11.6 CEREBRAL SPINAL FLUID
12 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY STAGES
12.1 OVERVIEW
12.2 STAGE 0
12.3 STAGE I
12.4 STAGE II
12.5 STAGE III
12.6 STAGE IV
13 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY AGE
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
14 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY TYPE
14.1 OVERVIEW
14.2 SMALL CELL LUNG CANCER
14.2.1 CIRCULATING TUMOR CELL
14.2.1.1. IMMUNE ENRICHMENT METHOD
14.2.1.1.1. IMMUNOMAGNETIC BEAD METHOD
14.2.1.1.1.1 POSITIVE-ENRICHMENT METHOD
14.2.1.1.1.2 NEGATIVE-ENRICHMENT METHOD
14.2.1.1.2. IMMUNOADSORPTION METHOD
14.2.1.2. PHYSICAL ENRICHMENT METHOD
14.2.2 CIRCULATING TUMOR DNA
14.2.2.1. NEXT GENERATION SEQUENCING
14.2.2.2. REAL TIME PCR
14.2.2.3. DIGITAL DROPLET PCR
14.2.2.4. SCORPION AMPLIFICATION REFRACTORY MUTATION SYSTEMS
14.2.2.5. PEPTIDE NUCLEIC ACID‐LOCKED NUCLEIC ACID PCR
14.2.3 MICRO RNA
14.2.3.1. RNA SEQUENCENCING
14.2.3.2. MICROARRAYS
14.2.3.3. REAL TIME PCR
14.2.4 TUMOR-EDUCATED PLATELETS
14.2.4.1. ULTRA-DEEP
14.2.4.2. MASSIVE PARALLEL
14.2.4.3. LONG-READ SEQUENCING
14.2.5 TUMOUR DERIVED EXOSOMES
14.2.5.1. EV ARRAY
14.2.5.2. IMMUNOAFFINITY‐BASED TECHNIQUESULTRACENTRIFUGATION
14.2.5.2.1. ELISA
14.2.5.2.2. WESTERN BLOT
14.2.5.3. DENSITY GRADIENT
14.2.5.4. MICROFLUIDICS‐BASED
14.2.5.5. NANOTECHNOLOGY
14.2.5.6. OTHERS
14.3 NON SMALL CELL LUNG CANCER (NSCLC)
14.3.1 CIRCULATING TUMOR CELL
14.3.1.1. IMMUNE ENRICHMENT METHOD
14.3.1.1.1. IMMUNOMAGNETIC BEAD METHOD
14.3.1.1.1.1 POSITIVE-ENRICHMENT METHOD
14.3.1.1.1.2 NEGATIVE-ENRICHMENT METHOD
14.3.1.1.2. IMMUNOADSORPTION METHOD
14.3.1.2. PHYSICAL ENRICHMENT METHOD
14.3.2 CIRCULATING TUMOR DNA
14.3.2.1. NEXT GENERATION SEQUENCING
14.3.2.2. REAL TIME PCR
14.3.2.3. DIGITAL DROPLET PCR
14.3.2.4. SCORPION AMPLIFICATION REFRACTORY MUTATION SYSTEMS
14.3.2.5. PEPTIDE NUCLEIC ACID‐LOCKED NUCLEIC ACID PCR
14.3.3 MICRO RNA
14.3.3.1. RNA SEQUENCENCING
14.3.3.2. MICROARRAYS
14.3.3.3. REAL TIME PCR
14.3.4 TUMOR-EDUCATED PLATELETS
14.3.4.1. ULTRA-DEEP
14.3.4.2. MASSIVE PARALLEL
14.3.4.3. LONG-READ SEQUENCING
14.3.5 TUMOUR DERIVED EXOSOMES
14.3.5.1. EV ARRAY
14.3.5.2. IMMUNOAFFINITY‐BASED TECHNIQUESULTRACENTRIFUGATION
14.3.5.2.1. ELISA
14.3.5.2.2. WESTERN BLOT
14.3.5.3. DENSITY GRADIENT
14.3.5.4. MICROFLUIDICS‐BASED
14.3.5.5. NANOTECHNOLOGY
14.3.5.6. OTHERS
15 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 ASSOCIATED LABS
15.4 INDEPENDENT DIAGNOSTIC LABORATORIES
15.5 DIAGNOSTIC IMAGING CENTERS
15.6 CANCER RESEARCH INSTITUTES
15.7 OTHERS
16 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
17 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, BY REGION
17.1 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 U.K.
17.3.3 ITALY
17.3.4 FRANCE
17.3.5 SPAIN
17.3.6 RUSSIA
17.3.7 SWITZERLAND
17.3.8 TURKEY
17.3.9 BELGIUM
17.3.10 NETHERLANDS
17.3.11 DENMARK
17.3.12 SWEDEN
17.3.13 POLAND
17.3.14 NORWAY
17.3.15 FINLAND
17.3.16 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 SINGAPORE
17.4.6 THAILAND
17.4.7 INDONESIA
17.4.8 MALAYSIA
17.4.9 PHILIPPINES
17.4.10 AUSTRALIA
17.4.11 NEW ZEALAND
17.4.12 VIETNAM
17.4.13 TAIWAN
17.4.14 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRAZIL
17.5.2 ARGENTINA
17.5.3 REST OF SOUTH AMERICA
17.6 MIDDLE EAST AND AFRICA
17.6.1 SOUTH AFRICA
17.6.2 EGYPT
17.6.3 BAHRAIN
17.6.4 UNITED ARAB EMIRATES
17.6.5 KUWAIT
17.6.6 OMAN
17.6.7 QATAR
17.6.8 SAUDI ARABIA
17.6.9 REST OF MIDDLE EAST AND AFRICA
17.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL LUNG CANCER LIQUID BIOPSY MARKET, COMPANY PROFILE
19.1 BIOCOMPARE
19.1.1 COMPANY OVERVIEW
19.1.2 REVENUE ANALYSIS
19.1.3 GEOGRAPHIC PRESENCE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 HORIZON DISCOVERY LTD.
19.2.1 COMPANY OVERVIEW
19.2.2 REVENUE ANALYSIS
19.2.3 GEOGRAPHIC PRESENCE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPEMENTS
19.3 F. HOFFMANN-LA ROCHE LTD
19.3.1 COMPANY OVERVIEW
19.3.2 REVENUE ANALYSIS
19.3.3 GEOGRAPHIC PRESENCE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPEMENTS
19.4 QIAGEN
19.4.1 COMPANY OVERVIEW
19.4.2 REVENUE ANALYSIS
19.4.3 GEOGRAPHIC PRESENCE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPEMENTS
19.5 AGENA BIOSCIENCE, INC.
19.5.1 COMPANY OVERVIEW
19.5.2 REVENUE ANALYSIS
19.5.3 GEOGRAPHIC PRESENCE
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPEMENTS
19.6 4BASECARE.
19.6.1 COMPANY OVERVIEW
19.6.2 REVENUE ANALYSIS
19.6.3 GEOGRAPHIC PRESENCE
19.6.4 PRODUCT PORTFOLIO
19.6.5 RECENT DEVELOPEMENTS
19.7 BIONOVITUS, LLC.
19.7.1 COMPANY OVERVIEW
19.7.2 REVENUE ANALYSIS
19.7.3 GEOGRAPHIC PRESENCE
19.7.4 PRODUCT PORTFOLIO
19.7.5 RECENT DEVELOPEMENTS
19.8 BIOCARTIS NV
19.8.1 COMPANY OVERVIEW
19.8.2 REVENUE ANALYSIS
19.8.3 GEOGRAPHIC PRESENCE
19.8.4 PRODUCT PORTFOLIO
19.8.5 RECENT DEVELOPEMENTS
19.9 EPIGENOMICS AG
19.9.1 COMPANY OVERVIEW
19.9.2 REVENUE ANALYSIS
19.9.3 GEOGRAPHIC PRESENCE
19.9.4 PRODUCT PORTFOLIO
19.9.5 RECENT DEVELOPEMENTS
19.1 LUNGLIFE AI, INC.
19.10.1 COMPANY OVERVIEW
19.10.2 REVENUE ANALYSIS
19.10.3 GEOGRAPHIC PRESENCE
19.10.4 PRODUCT PORTFOLIO
19.10.5 RECENT DEVELOPEMENTS
19.11 PERSONAL GENOME DIAGNOSTICS INC.
19.11.1 COMPANY OVERVIEW
19.11.2 REVENUE ANALYSIS
19.11.3 GEOGRAPHIC PRESENCE
19.11.4 PRODUCT PORTFOLIO
19.11.5 RECENT DEVELOPEMENTS
19.12 MEDGENOME
19.12.1 COMPANY OVERVIEW
19.12.2 REVENUE ANALYSIS
19.12.3 GEOGRAPHIC PRESENCE
19.12.4 PRODUCT PORTFOLIO
19.12.5 RECENT DEVELOPEMENTS
19.13 SYSMEX EUROPE SE
19.13.1 COMPANY OVERVIEW
19.13.2 REVENUE ANALYSIS
19.13.3 GEOGRAPHIC PRESENCE
19.13.4 PRODUCT PORTFOLIO
19.13.5 RECENT DEVELOPEMENTS
19.14 THERMO FISHER SCIENTIFIC INC.
19.14.1 COMPANY OVERVIEW
19.14.2 REVENUE ANALYSIS
19.14.3 GEOGRAPHIC PRESENCE
19.14.4 PRODUCT PORTFOLIO
19.14.5 RECENT DEVELOPEMENTS
19.15 STILLA
19.15.1 COMPANY OVERVIEW
19.15.2 REVENUE ANALYSIS
19.15.3 GEOGRAPHIC PRESENCE
19.15.4 PRODUCT PORTFOLIO
19.15.5 RECENT DEVELOPEMENTS
19.16 INIVATA LTD
19.16.1 COMPANY OVERVIEW
19.16.2 REVENUE ANALYSIS
19.16.3 GEOGRAPHIC PRESENCE
19.16.4 PRODUCT PORTFOLIO
19.16.5 RECENT DEVELOPEMENTS
19.17 ALIGENT
19.17.1 COMPANY OVERVIEW
19.17.2 REVENUE ANALYSIS
19.17.3 GEOGRAPHIC PRESENCE
19.17.4 PRODUCT PORTFOLIO
19.17.5 RECENT DEVELOPEMENTS
19.18 CELLCARTA
19.18.1 COMPANY OVERVIEW
19.18.2 REVENUE ANALYSIS
19.18.3 GEOGRAPHIC PRESENCE
19.18.4 PRODUCT PORTFOLIO
19.18.5 RECENT DEVELOPEMENTS
19.19 NEOGENOMICS LABORATORIES.
19.19.1 COMPANY OVERVIEW
19.19.2 REVENUE ANALYSIS
19.19.3 GEOGRAPHIC PRESENCE
19.19.4 PRODUCT PORTFOLIO
19.19.5 RECENT DEVELOPEMENTS
19.2 BOREAL GENOMICS INC.
19.20.1 COMPANY OVERVIEW
19.20.2 REVENUE ANALYSIS
19.20.3 GEOGRAPHIC PRESENCE
19.20.4 PRODUCT PORTFOLIO
19.20.5 RECENT DEVELOPEMENTS
19.21 BIO-RAD LABORATORIES, INC.
19.21.1 COMPANY OVERVIEW
19.21.2 REVENUE ANALYSIS
19.21.3 GEOGRAPHIC PRESENCE
19.21.4 PRODUCT PORTFOLIO
19.21.5 RECENT DEVELOPEMENTS
19.22 SAGA DIAGNOSTICS
19.22.1 COMPANY OVERVIEW
19.22.2 REVENUE ANALYSIS
19.22.3 GEOGRAPHIC PRESENCE
19.22.4 PRODUCT PORTFOLIO
19.22.5 RECENT DEVELOPEMENTS
19.23 SERACARE
19.23.1 COMPANY OVERVIEW
19.23.2 REVENUE ANALYSIS
19.23.3 GEOGRAPHIC PRESENCE
19.23.4 PRODUCT PORTFOLIO
19.23.5 RECENT DEVELOPEMENTS
19.24 ILLUMINA, INC.
19.24.1 COMPANY OVERVIEW
19.24.2 REVENUE ANALYSIS
19.24.3 GEOGRAPHIC PRESENCE
19.24.4 PRODUCT PORTFOLIO
19.24.5 RECENT DEVELOPEMENTS
19.25 MENARINI SILICON BIOSYSTEMS
19.25.1 COMPANY OVERVIEW
19.25.2 REVENUE ANALYSIS
19.25.3 GEOGRAPHIC PRESENCE
19.25.4 PRODUCT PORTFOLIO
19.25.5 RECENT DEVELOPEMENTS
19.26 BIOMARK DIAGNOSTICS INC.
19.26.1 COMPANY OVERVIEW
19.26.2 REVENUE ANALYSIS
19.26.3 GEOGRAPHIC PRESENCE
19.26.4 PRODUCT PORTFOLIO
19.26.5 RECENT DEVELOPEMENTS
19.27 LUCENCE HEALTH INC.
19.27.1 COMPANY OVERVIEW
19.27.2 REVENUE ANALYSIS
19.27.3 GEOGRAPHIC PRESENCE
19.27.4 PRODUCT PORTFOLIO
19.27.5 RECENT DEVELOPEMENTS
19.28 QUEST DIAGNOSTICS INCORPORATED.
19.28.1 COMPANY OVERVIEW
19.28.2 REVENUE ANALYSIS
19.28.3 GEOGRAPHIC PRESENCE
19.28.4 PRODUCT PORTFOLIO
19.28.5 RECENT DEVELOPEMENTS
19.29 ELEMENT BIOSCIENCES
19.29.1 COMPANY OVERVIEW
19.29.2 REVENUE ANALYSIS
19.29.3 GEOGRAPHIC PRESENCE
19.29.4 PRODUCT PORTFOLIO
19.29.5 RECENT DEVELOPEMENTS
19.3 VORTEX BIOSCIENCES
19.30.1 COMPANY OVERVIEW
19.30.2 REVENUE ANALYSIS
19.30.3 GEOGRAPHIC PRESENCE
19.30.4 PRODUCT PORTFOLIO
19.30.5 RECENT DEVELOPEMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
